Event Details
January 01, 2009
Description
FDA gave green light for Geron clinical trial.
Participants (2)
| Name | Type | Mentions | |
|---|---|---|---|
| FDA | person | 0 | View Entity |
| Geron | organization | 2 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_013482.jpg
This document is an email dated November 23, 2012, from Steven Victor MD to a redacted recipient. The email contains the full text of a special report by Peter Winter regarding the positive outlook for stem cell therapy in the US following the re-election of Barack Obama. The report discusses the regulatory environment, including the role of the FDA and NIH, specific legal challenges (Sherley v. Sebelius), and the activities of the biotech company Geron.
Related Events
Events with shared participants
FDA convened a meeting to analyze data on the drug Praluent, leading to its approval for a larger group of patients than expected.
Date unknown • U.S.
The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia and certain types of heart disease.
Date unknown
FDA approval of Marinol and Cesamet
1985-01-01 • USA
Marinol approved for treatment of anorexia associated with AIDS
1992-01-01 • USA
Syndros approved by the FDA
2016-01-01 • USA
FDA accepted GW Pharmaceuticals’ New Drug Application (NDA) for the cannabis-derived drug Epidiolex.
2017-10-01 • USA
FDA published industry guidance on botanical drug development.
2016-12-01 • USA
Previous FDA guidance on botanical drugs issued.
2004-06-01 • USA
FDA convened meeting to analyze drug data.
Date unknown
Expected FDA approval of a cannabis-derived pharmaceutical
2018-01-01 • USA
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event